Zimmer Biomet raised its FY 2026 financial guidance after reporting broad-based Q3 sales growth, driven by Hips, S.E.T., and ...

A new host-response blood test from Beckman Coulter and MeMed delivers bacterial-vs-viral results in 15 minutes, aiding ...

The characterization of digital health technologies in vision care has transitioned from a theoretical taxonomy to a highly ...

FDA flagged safety alerts for Teleflex guidewires/catheters over coating particles and Intersurgical breathing tubes over ...

FDA is seeking feedback on a discussion paper weighing the benefits and risks of autonomous and remote-controlled robotic ...

J&J's venture arm JJDC leads financing for Francis Medical's Vanquish prostate ablation system, supporting FDA PMA path for ...

Oura will acquire AI virtual care company Counsel Health for $625 million in an all-cash deal expected to close by end of ...

Hyperfine's Q3 revenue topped cash burn for the first time, marking a major step toward capital efficiency and profitability.

AAHKS warns Medicare's 2027 cuts to hip and knee replacement payments threaten procedure volumes, tech adoption, and medtech ...

FDA denied Novocure's PMA for Optune Mya, citing a lack of clinical benefit evidence, though no safety concerns were raised.

Simtra's Mike Schaefer on how the GLP-1 boom is reshaping CDMO strategy, from regional manufacturing to cold-chain capacity.

Forget Congress — the real medtech question for 2027 is whether hospital customers can still afford capital equipment ...